• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Xintela

0,19 SEK

-3,75 %

Mindre end 1K følgere

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-3,75 %
-22,06 %
-17,03 %
-32,22 %
-24,21 %
-55,40 %
-26,13 %
-88,68 %
-91,60 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Læs mere
Markedsværdi
165,79 mio. SEK
Aktieomsætning
1,46 t SEK
Omsætning
2,28 mio.
EBIT %
-2.045,75 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
28.8
2026

Delårsrapport Q2'26

27.11
2026

Delårsrapport Q3'26

26.2
2027

Årsrapport '26

Eksterne analyser4.6.2026, 06.58

Xintela: Completing another phase I/IIa study - VH Corp

• Considering the alternatives in wound treatment • Discussions about investigator-initiated studies continue • We keep our fair value at SEK 1.04 per share On the day of the Q1 report, Xintela announced positive results of its phase I/IIa study of XSTEM...

Xintela
Pressemeddelelse4.6.2026, 06.00

Västra Hamnen Market Focus: Xintela: Completing another phase I/IIa study

Xintela
Selskabsmeddelelse29.5.2026, 12.25

Xintela AB Interim Report January - March 2026

Xintela

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse29.5.2026, 08.00

Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela
Selskabsmeddelelse28.5.2026, 11.00

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela
Pressemeddelelse12.5.2026, 11.15

Xintela granted patent in Japan for XSTEM® treatment of acute respiratory distress syndrome (ARDS)

Xintela
Selskabsmeddelelse30.4.2026, 05.50

Xintela AB publishes Annual Report 2025

Xintela
Pressemeddelelse14.4.2026, 11.05

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela
Pressemeddelelse13.4.2026, 21.15

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

Xintela
Eksterne analyser3.3.2026, 08.21

Xintela: Moving forward with XSTEM - VH Corp

* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated studies * We keep our fair value of SEl 1.04 per share Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan...

Xintela
Pressemeddelelse3.3.2026, 08.15

Västra Hamnen Market Focus: Xintela: Moving forward with XSTEM

Xintela
Selskabsmeddelelse27.2.2026, 06.00

Xintela AB Year-end Report 2025

Xintela
Pressemeddelelse17.2.2026, 10.07

Västra Hamnen Market Focus: Professor Hall comments on Xintela's study results

Xintela
Pressemeddelelse13.2.2026, 13.50

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela
Eksterne analyser12.12.2025, 10.17

Xintela: Extending the financial runway - VH Corp

* The rights issue added MSEK 42 before loan offset * Fenja Capital II provides loan facility of MSEK 20 * After dilution, our fair value amounts to SEK 1.04 (1.28) per share Xintela’s recent rights issue was subscribed to 58 per cent, corresponding ...

Xintela
Pressemeddelelse12.12.2025, 09.49

Västra Hamnen Market Focus: Xintela: Extending the financial runway

Xintela
Eksterne analyser12.11.2025, 09.20

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela
Pressemeddelelse12.11.2025, 09.15

Västra Hamnen Market Focus: Xintela: Focus on study results and financing

Xintela
Selskabsmeddelelse4.11.2025, 17.05

Xintela AB Interim Report January - September 2025

Xintela
Pressemeddelelse30.10.2025, 07.15

Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

Xintela